The first batch of the adjunct COVID therapy anti-COVID drug, 2-deoxy-D-glucose (2-DG), was released by Defence Minister Shri Rajnath Singh in New Delhi on May 17, 2021
- An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr Reddy’s Laboratories (DRL), Hyderabad.
- Secretary Department of Defence R&D and Chairman DRDO Dr G Satheesh Reddy expressed confidence that the anti-COVID drug will help the patients recover from the deadly virus, hoping that DRL, Hyderabad will take it forward and soon make the drug available for the patients. He also thanked Raksha Mantri for his continuous guidance and support.
